Table 1. Chemotherapy schedule of the... | American Society of Hematology

Table 1.

Chemotherapy schedule of the PONALFIL trial

Phase	Route	Dose	Days
Induction*
Ponatinib	By mouth	30 mg	Until consolidation
Vincristine (maximum 2 mg)	IV	1.5 mg/m²	1, 8, 15, 22
Daunorubicin	IV	45 mg/m²	1, 8, 15, 22
Prednisone	IV	60 mg/m²	1-14
	IV	30 mg/m²	15-21
	IV	15 mg/m²	22-28
Triple IT†	IT		1, 28
Consolidation
Ponatinib	By mouth	30 mg	Until HSCT
Methotrexate	IV	1.5 g/m²	1, 28, 56
Mercaptopurine	By mouth	50 mg/m²	1-7, 28-35, 56-63
Etoposide	IV	100 mg/m²	14, 42
Cytarabine	IV	1000 mg/m²/12h	14, 15, 42, 43
Triple IT†	IT		1, 28, 56
Maintenance
Ponatinib‡	By mouth	30 mg (first year) 15 mg (second year)	Daily

Phase	Route	Dose	Days
Induction*
Ponatinib	By mouth	30 mg	Until consolidation
Vincristine (maximum 2 mg)	IV	1.5 mg/m²	1, 8, 15, 22
Daunorubicin	IV	45 mg/m²	1, 8, 15, 22
Prednisone	IV	60 mg/m²	1-14
	IV	30 mg/m²	15-21
	IV	15 mg/m²	22-28
Triple IT†	IT		1, 28
Consolidation
Ponatinib	By mouth	30 mg	Until HSCT
Methotrexate	IV	1.5 g/m²	1, 28, 56
Mercaptopurine	By mouth	50 mg/m²	1-7, 28-35, 56-63
Etoposide	IV	100 mg/m²	14, 42
Cytarabine	IV	1000 mg/m²/12h	14, 15, 42, 43
Triple IT†	IT		1, 28, 56
Maintenance
Ponatinib‡	By mouth	30 mg (first year) 15 mg (second year)	Daily

Pre-phase with prednisone 60 mg/m² and triple IT was given for a maximum of 1 week, while ALL was fully characterized.

Triple IT with methotrexate (15 mg), cytarabine (30 mg), and hydrocortisone (20 mg).

After alloHSCT, only if molecular disease persisted or reappeared.